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Insertion of the 17-nucleotide promoter region for the bovine coronavirus N gene as part of a 27-nucleotide cassette
into the open reading frame of a cloned synthetic defective-interfering (DI) RNA resulted in synthesis of subDI RNA transcripts
from the replicating DI RNA genome. Duplicating and triplicating the promoter sequence in tandem caused a progressive
increase in the efficiency of subgenomic mRNA synthesis despite a concurrent decrease in the rate of DI RNA accumulation
that was not specific to the promoter sequences being added. Although initiation of transcription (leader fusion) occurred
at each of the three promoter sites in the tandem construct, almost all of the transcripts were found as a product of the
most downstream (3 *-most on the genome) promoter. These results show that enhancement of subgenomic mRNA synthesis
is a property that can reside within sequence situated near the promoter. A possible role for the plus strand in the
downstream promoter choice is suggested. q 1996 Academic Press, Inc.
During bovine coronavirus replication, a 3 *-coterminal coworkers (11) have shown with cloned replicating defec-
tive-interfering (DI) RNAs of MHV that the rate of mRNAnested set of subgenomic mRNAs that coordinately peak
synthesis from an engineered intergenic promoter does notin abundance at around 6 hr postinfection is made. At
necessarily correlate with the degree of sequence comple-this time, the mRNA species are not equal in number, but
mentarity. Sequences distantly upstream from the promoterrather the shorter 3 *-proximal species are progressively
in MHV, furthermore, may enhance transcription (12).more abundant. The molar differences range from 1 for
A second model used to explain the origin of differinggenome (mRNA 1) to 1000 for mRNA 7 (N gene mRNA),
mRNA levels (13) was based on the observations thatthe smallest mRNA species (1). Although exceptions oc-
subgenomic mRNA-length minus strands function ascur, this general pattern of mRNA regulation holds true
components of replicative intermediates (13, 14). Thisfor all coronaviruses (reviewed in 2).
model predicted that subgenomic minus-strand RNAsExplanations for the differing mRNA levels have reflected
are generated by an interruption of minus-strand synthe-views on how mRNAs are generated. In the leader-primed
sis at attenuating intergenic sites. A greater abundancetranscription model, mRNAs are generated from a genome-
of 5*-proximal minus-strand templates would be ex-length minus strand (antigenome) by priming from a free
pected that would, in turn, generate progressively moreleader at intergenic promoter sites (3, 4). The original model
abundant 3 *-proximal mRNAs. Transcription initiationpredicted that the degree of base complementarity between
would result from the use of 5*-terminal AGAUUUG pro-the promoter region and the priming free leader would
moter motifs or perhaps from a spliced antileader on thedetermine promoter strength. Although this prediction was
subgenomic minus strands (13).supported by the degree of base pairing and mRNA accu-
A third model was also based on the presence ofmulation rates in murine hepatitis virus (MHV) (5, 6), the
subgenomic minus-strand RNAs (1, 14, 15) but predictedsame correlation was not found in infectious bronchitis
that mRNAs, once generated (by whatever mechanism),virus (7), calling this mechanism of regulation into question.
would undergo amplification by replication through theIn addition, Makino and coworkers (8–10) and Spaan and
use of terminal promoter sequences (1, 14). Conceivably,
for either model 1 or 2, subgenomic molecules pos-
sessing intergenic promoters could function as tem-1 Current address: Laboratory of Molecular Microbiology, National
Institute of Allergy and Infectious Diseases, National Institutes of plates for transcription thus creating a cascading effect
Health, Bethesda, MD 20892. that would preferentially amplify 3 *-proximal mRNAs (16).2 Current address: Institute of Biochemistry, National Yang-Ming Uni-
For models 1 and 2, flanking sequences at intergenicversity, Taipei, Taiwan.
promoter sites might be expected to influence transcrip-3 To whom reprint requests should be addressed. Fax: (423) 974-
4007; E-mail: Brian@utkvx.utk.edu. tion rates.
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the initial cloning) encoding the 1- to 23-aa neutralizing
epitope of herpes simplex virus (HSV) gD (18) into the
mung bean nuclease blunt-ended Bsu36.1 site of pDrep1
(17). A 3-nt overdigestion at the Bsu36.1 site caused an
in-frame insertion of 81 rather than 84 nt.
For transfection and transcription analysis, cells in-
fected with BCV were transfected as previously de-
scribed (17), except that the helper virus was a stock
that contained no wild-type DI RNA (as determined by
Northern analysis), and 1 mg RNA per 35-mm plate was
used for transfection. At 24 hr posttransfection superna-
tant was collected and used to infect fresh HRT cells
from which cytoplasmic RNA was isolated at 9 hr postin-
fection. RNA was analyzed by quantitative Northern blot
hybridization using the AMBIS photoanalytic imaging
system (AMBIS, Inc., San Diego, CA) following hybridiza-
tion with end-labeled oligonucleotide 8 which hybridizes
to the plus strand of the TGEV reporter sequence (17).
For primer extension analysis, approximately 1 pmol
FIG. 1. Structures of the mutated DI RNA genome and of the most
of oligonucleotide 8, 5*-end-labeled with 32P to a specificabundant subgenomic transcript (mRNA1) arising from each construct.
activity of 1.3 1 106 cpm/pmol (Cerenkov counts), waspDrep1 is the cloned reporter-containing BCV DI RNA, and the diagram
shows the 5*-terminal bases in the T7 polymerase-generated transcript used with 2.5 mg of cytoplasmic RNA for the primer exten-
and positions of the 30-nt reporter sequence, the Bsu36.1 restriction sion reaction (19). Products were analyzed on a DNA
endonuclease site, and primers 1 and 2 used for RT–PCR amplification sequencing gel of 6% polyacrylamide and quantitated
of leader-RNA fusion regions within the DI RNA and subDI RNA tran-
by scanning the autoradiogram with a BioRad imagingscripts. Structures of pDrepIS1, pDrepIS2, and pDrepIS3 contain 1, 2,
densitometer.and 3 intergenic sequences, respectively. The potential codons for the
initiation of translation on the subDI RNA transcripts are identified with For sequencing and cloning of RT–PCR products,
an underline. cDNA synthesis from cytoplasmic RNA and sequencing
of asymmetrically amplified PCR products were carried
out as previously described (20) except that oligonucleo-
tide 8b, 5*CATGGCACCATCCTTGGCA3 *, a 3 *-truncatedIn this study we have directly examined the effect of
a multimerized internal promoter (termed intergenic se- version of oligonucleotide 8, was used for the reverse
transcriptase reaction. For sequencing the 5* end of DIquence, IS) on mRNA abundance. For this, a cDNA clone
of a naturally occurring bovine coronavirus (BCV) DI RNA RNA subgenomic mRNAs, oligonucleotide L(0), 5*GCG-
GGATGCACGCACGCAAATCGCTC3 *, which binds toengineered to contain a reporter, an in-frame 30-nt se-
quence from the N gene of porcine transmissible gastro- bases 7 to 33 of BCV leader plus strand, and oligonucleo-
tide 8 were used. For sequencing genomic DI RNA, oligo-enteritis virus (TGEV), and called pDrep1 (17) was used
for intergenic sequence insertion (Fig. 1). We have shown nucleotide N(0), 5*AGAGCGTCCTTTGGAAATCGTTCT-
GG3*, which binds to bases 34 to 59 in the N ORF, andthat T7 RNA polymerase-generated transcripts of pDrep1
linearized at the Mlu1 site undergo replication and subse- oligonucleotide 8 were used. Cloning of PCR-amplified
products was carried out as recommended by the manu-quent packaging after transfection into helper virus-in-
fected cells (17). To make pDrepIS1, two 27mer oligonu- facturer for TA cloning (Invitrogen).
From studies of genomic sequences for the mammaliancleotides, A1 (5*TCAGGAATATCTAAACTTTAAGATGAA-
3 *) and A2 (5*TGATTCATCTTAAAGTTTAGATATTCC3*), coronaviruses BCV (Table 1), MHV, and TGEV, the heptam-
eric intergenic sequence UCUAAAC has emerged as awere annealed (creating a Bsu36.1-compatible site at its
5* end, virus sense) and inserted at the unique Bsu36.1 consensus element postulated to be the core promoter for
directing viral subgenomic transcription. This was directlysite 52 nt upstream of the reporter sequence in pDrep1
(Fig. 1). Upon insertion the Bsu36.1 site was regenerated tested by Makino and Joo (9) in a study that demonstrated
the UCUAAAC heptad to be sufficient for subgenomic tran-at the 5* end. To construct pDrepIS2 and pDrepIS3, oligo-
nucleotides A1 and A2 were phosphorylated, annealed, scription from a site within the ORF of a replicating DI RNA
of MHV. Promoter activity, however, became optimal whenand ligated with Bsu36.1-digested, dephosphorylated
pDrepIS1. pDrep-gpD81 was generated by cloning an an intergenic sequence of 18 nt from the N gene, a region
showing full complementarity to the 3* end of MHV geno-87-nt blunt-ended fragment (5*ccAAATATGCCTTG-
GTGGATGCCTCTCTCAAGATGGCCGACCCCAATCGC- mic leader, the postulated primer of transcription in the
leader priming model (3, 4, 23), was used.TTTCGCGGCAAAGACCTTC CGgtc ctggacgggaatt
3*; lowercase letters refer to primer sequences used in BCV is a close relative of MHV (24, 25), yet differs
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TABLE 1 mRNA and DI genome accumulation for these were com-
pared to those for pDrep1 and pDrepIS1 (Fig. 2A, lanesIntergenic Sequences on the Bovine Coronavirus Genome
1 through 4). Quantitative Northern analysis using the
Gene reporter-detecting probe demonstrated that synthetic
immediately transcripts of pDrepIS1, pDrepIS2, and pDrepIS3 repli-
downstream of cated and generated subgenomic mRNA and that prog-
the intergenic
eny genomes were packaged. Whereas the accumulatedsequence Intergenic sequencea
amounts of subgenomic mRNA remained nearly the
Pol 5*auaaUCUAAACuuuaua3*b same for pDrepIS1, pDrepIS2, and pDrepIS3, the
. ............ amounts of DI RNA genome progressively decreased
N 5*aauaUCUAAACuuuaag3* (Fig. 2A, lanes 2–4), resulting in subgenomic to genomic
M 5*uuaaUCCAAACauuaug3*
RNA molar ratios of 0.25, 0.65, and 1.20, respectively.9.6 kDa 5*caaaUCCAAACauuaug3*
This demonstrated an apparent progressive increase in12.7 kDa 5*uuuaggUAgACcuuaua3*
S 5*auaaUCUAAACauguug3* the efficiency of transcription (Fig. 3). To determine
HE 5*gaagaCUAAACucagug3* whether the inhibition in DI RNA accumulation was a
Consensus 5*UCUAAAC3* function of the subgenomic transcription process or was
27mer cassette 5*ucaggaauaUCUAAACuuuaagaugaa3*c
possibly the result of another function of an inserted
sequence, an 81-nt sequence with no known promoter-a Documented in Refs. 20–22.
b The 5*-terminal 65-nucleotide BCV genomic leader terminates at like motif was added at the Bsu36.1 site to form pDrep-
base 6 in this sequence. Bases identical between the extended geno- gpD81, and transcripts were tested for replication. An
mic leader and the intergenic sequence immediately preceding the N inhibition of DI RNA replication equivalent to that for
gene are identified with dots.
pDrepIS3 but without subgenomic transcription wasc Underlined region in the 17-nucleotide intergenic sequence found
found for pDrep–gpD81 RNA (Fig. 2B), suggesting thatimmediately preceding the N gene. The engineered start codon for
subgenomic mRNA is boxed. the inhibition of replication in pDrepIS constructs was
not necessarily a result of the transcription but was due
to an added sequence at this site in the DI RNA genome.
By probing a blot identical to that in Fig. 2A, lanes 1–4,from MHV in two respects with regard to the relationship
between genomic leader and intergenic sequence. (i) with an oligonucleotide recognizing the N gene se-
quence, and hence all viral mRNA species, it was deter-The region of contiguous sequence identity between the
extended genomic leader and the intergenic sequence mined that virus from passage 1 replicated nearly equally
well in all infected plates (Fig. 2A, lanes 5–8).preceding the N gene is 12 not 18 nt (Table 1). (ii) Repeti-
tive UCUAA sequences, thought to yield alternative fu- The pattern of Northern blot analysis (Fig. 2A) sug-
gested that the subgenomic transcripts of pDrepIS1,sion sites in MHV (6, 26 –28), do not exist in the BCV
leader or its flanking sequence and hence may be a pDrepIS2, and pDrepIS3 were the same size since incre-
mental differences of 27 nt would have been revealed insequence phenomenon related to the invariant mRNA
fusion junction patterns found in BCV (20). To determine, an agarose gel of this design. These differences, for
example, could be discerned among the DI genomictherefore, whether the analogous region in BCV could
direct subgenomic transcription, the analogous 17-nt in- RNAs. In the first approach used to characterize the
leader-mRNA fusion sites for subgenomic mRNAs, RT –tergenic sequence from the BCV genome (a base was
deleted from the 3 * end to conform to the homologous PCR analysis (Fig. 2C) was carried out on RNA samples
prepared from the first virus passage, the same RNAregion as defined in Ref. 7) (Table 1) was inserted as
part of a 27-nt cassette into the unique Bsu36.1 site of used for Northern blot hybridization analysis (Fig. 2A).
As suggested by Northern hybridization data, there waspDrep1 to form pDrepIS1 (Fig. 1), and transcripts were
tested for replication and subgenomic transcription. The revealed a preferential usage of the 3 *-most promoter
for leader fusion. The identity of the abundant DI mRNAcassette was designed to maintain the DI RNA ORF, a
cis-acting requirement for BCV DI RNA replication (17), band 1 in Fig. 2C, lanes 2, 3, and 4, was further ascer-
tained by direct PCR sequencing, and that of DI mRNAsand to insert an AUG start codon just downstream of the
leader on the subgenomic transcript. Both replication of 1 and 2 by the sequencing cDNA-cloned cDNA products
(data not shown). The DI mRNA 3 band could not bethe DI RNA and generation of subgenomic mRNA from
pDrepIS1 were observed (results were similar to those cloned as cDNA. These results showed that the down-
stream-most promoter site was predominantly used byin Fig. 2A, lane 2).
To determine what effects multimerization of the pro- pDrepIS2 and pDrepIS3 and that the junction sequence
in each subgenomic transcript demonstrated no hetero-moter sequence would have on subgenomic mRNA syn-
thesis, the cassette was placed in two (pDrepIS2) and geneity and was therefore the same as for N mRNA (20;
Fig. 1, and data not shown). The DI mRNA 3 fusion sitethree (pDrepIS3) adjacent copy repeats within the
pDrep1 ORF sequence, and the rates of subgenomic could not be confirmed by sequencing but the position
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FIG. 2. Effect of tandemizing the internal promoter on accumulation of DI genomic RNA and subgenomic mRNA. (A) Northern blot analysis
showing relative amounts of DI genomic RNA and subgenomic mRNAs. Equal amounts of cytoplasmic RNA from cells infected with passage 1
virus harvested from the respective transfection experiment were analyzed with 32P-labeled oligonucleotide probe. Lanes 1 through 4 were probed
with reporter plus-strand-detecting probe (oligonucleotide 8) to identify DI RNA genome and subgenomic transcripts, and lanes 5 through 8 were
probed with N plus-strand-detecting probe (oligonucleotide N/) to identify helper virus RNA as well as DI RNA species (17). (B) Northern blot
analysis showing inhibition of DI RNA replication as a function of the 81-nt HSV gD (nonpromoter) insert. Probing was done as described in A,
lanes 1 through 4. (C) RT–PCR analysis showing the relative amounts of genomic DI RNA and subgenomic mRNAs. Cytoplasmic RNA described
in A was used in an RT–PCR with primers 1 and 2, and the products were analyzed on an agarose gel of 3% and stained with ethidium bromide.
(D) Primer extension analysis. Lanes 1 through 6, radiolabeled primer (oligonucleotide 8) which binds to the reporter sequence 52 nt downstream from
the IS1 promoter sequence was extended on cytoplasmic RNA obtained from cells as indicated. The extended products were then electrophoresed on
a denaturing sequencing gel of 6% polyacrylamide. Lanes 7 through 10, products of dideoxynucleotidyl DNA sequencing using oligonucleotide 8
as the radiolabeled primer and pDrepIS3 DNA as the template. The predicted mRNA positions were determined from the DNA sequence.
of the PCR band (Fig. 2C) indicated its fusion site would genomic RNA accumulated with each additional pro-
moter sequence; (ii) there was an apparent progressivebe at or near the upstream-most position.
In the second approach to characterize leader-mRNA increase in the efficiency of transcription as judged by
the DI mRNA to genome ratios of 0.56, 1.63, and 3.24,fusion sites, a primer extension experiment was done on
the RNA using radiolabeled oligonucleotide 8 which for pDrepIS1, pDrepIS2, and pDrepIS3, respectively; and
(iii) the vast majority of transcripts came from the down-binds to the DI RNA reporter sequence. Since it can be
expected that the primer would bind alike to DI mRNAs stream-most (DI mRNA 1) position in pDrep1S2 and
pDrepIS3. For pDrepIS2 no DI mRNA 2 was found, andand DI genomic RNA, extended products should reflect
the relative amounts of template species. Except for the for pDrepIS3 little DI mRNA 2 and no DI mRNA 3 tran-
scripts were found. Although these results support thepDrep1 RNA, RNA samples in this experiment were the
same as those used in the Northern blot in Fig. 2A. The trend identified by Northern analysis (Fig. 2A), they can-
not be given a strict quantitative interpretation sinceextended products (Fig. 2D) showed the following: (i)
There was a progressive decrease in the amount of DI shorter products are favored in enzymatic extension re-
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however, demonstrate that a local sequence surrounding
a promoter region in the DI RNA genome can direct an
enhanced synthesis of subgenomic mRNA when synthe-
sis of that RNA is quantitated as a ratio of DI template
to subDI mRNA.
How might the downstream initiation site be deter-
mined in a tandem construct? An explanation we favor
is a scheme that is most consistent with the model in
which minus-strand RNA synthesis is attenuated at in-
tergenic sites to yield subgenomic minus-strand tem-
plates for transcription (13; model 2 above). The nascent
mRNA might then continue to amplify (1, 14; model 3FIG. 3. Relative molar amounts of DI genomic RNA and subgenomic
above). We speculate that the downstream selection in-mRNAs as determined by Northern blot analysis. Plotted values repre-
volves the positive-strand RNA in a template that is atsent the means from two separate preparations of synthetic transcripts
analyzed as described in Fig. 2A, lanes 2–4. Within each experiment least partially double-stranded. This view stems first from
the number of counts in individual RNA bands was compared to that the observation that nearly all coronavirus minus-strand
in the pDrepIS1 genome. RNAs, genomic and subgenomic, are found as compo-
nents of membrane-bound replication complexes in
which the plus and minus strands exist in nearly equimo-actions. To ensure that the replicating molecules had not
acquired mutations in the unused promoter regions that lar amounts (31) as apparent components of transcrip-
tionally active double-stranded molecules (13, 32). In ad-might have harmed promoter function, asymmetric RT –
PCR sequencing was carried out on cytoplasmic DI ge- dition, at least one viral protein, N, and a 55-kDa cellular
protein have been shown to bind to plus-strand leadernomic RNA bands in Fig. 2A with oligonucleotides 8 and
N(0). No mutations were found (not shown). in the region of the UCUAAAC consensus sequence (33–
35), suggesting that they may take part in transcriptionOne possible determinant for the strong initiation of
transcription from the IS1 promoter (fusion) site might initiation. The potential of N to multimerize (24, 26) might
also contribute to protein–protein interactions of the kindhave been a linkage between the transcription initiation
and the closely associated translation start site. This postulated for assembly of coronavirus transcription
complexes (11, 12). Many features of this view find prece-possibility was tested by converting the AUG at base 23
in the IS1 promoter to ACG in the pDrepIS1 construct dent in poliovirus for which both viral and cellular pro-
teins bind to the 5* terminus of the plus-strand genome(Fig. 1) by site-directed mutagenesis. Subgenomic tran-
scription rates were identical with the AUG and ACG and contribute mechanistically to initiation of plus-strand
synthesis (37, 38).codons at this site (data not shown). Thus, the mutation
did not prevent subgenomic transcription, making the Thus, transcription factors could bind to plus strands
at intergenic sites and interact with polymerase and othertranslation start codon an unlikely cause for the prefer-
ence of downstream transcription initiation in pDrepIS2 cofactors to initiate transcription on nascent subgenomic
minus strands as they are generated. In this scheme, theand pDrepIS3.
Our studies with a BCV DI RNA show results consis- most downstream site in the promoter series would be
chosen because it would have associated with it the firsttent with those of Makino and coworkers (8–10, 29) and
Spaan and coworkers (11, 30) with MHV DI RNA in which assembled complex encountered by the approaching
polymerase during minus-strand synthesis. On the basisit was shown first that synthesis of a subgenomic mRNA
can be induced by insertion of an intergenic promoter of recent studies with high-frequency leader recombina-
tion in BCV (39), we further envision that the polymerasesequence into the DI RNA and second that enhancement
of downstream subgenomic mRNA synthesis resulted might switch templates near the region of the intergenic
promoter to copy a leader (possibly one on genomic orwhen two or more promoters were placed in close prox-
imity. This pattern of mRNA synthesis from engineered subgenomic mRNAs) and thereby generate an anti-
leader. The nascent antileader-containing minus strandsDI RNAs of two separate coronaviruses, therefore, re-
flects the general pattern observed from the coronavirus would then serve as templates for synthesis of leader-
containing subgenomic plus strands and could conceiv-genome and would seem to validate the use of DI RNA
molecules for deciphering the mechanisms of mRNA ably be repeatedly used as template were mRNA to repli-
cate. A recent demonstration of in vivo transcription fromabundance regulation. The results of our experiments
did not allow us to discern among the postulated tem- the termini of subgenomic minus-strands would seem
consistent with this model (40). Our experimental system,plates for transcription, which include the DI antigenome,
nonreplicating subgenomic minus strands, and replicat- furthermore, may reflect a mechanism used by BCV in a
natural case of strong downstream selection betweening subgenomic minus strands (corresponding to the
three models of transcription described above). They do, two adjacent promoters (20). During synthesis of the
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